Biogen Inc

XMUN:IDP

Business Description

Sector

Health Care

Industry

Biotechnology

Headquarters

United States of America US

Employees

7 500

IPO date

Sep 17, 1991

Biogen is a biotechnology company that develops and sells medicines for serious diseases, with a long focus on conditions that affect the brain and nervous system. Its main products are prescription drugs for diseases such as multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, and certain rare neurological disorders. It also works on therapies for immunology and related areas, but its business is centered on specialty medicines that are prescribed by doctors rather than sold over the counter.

The company makes money mainly by selling branded drugs to hospitals, clinics, pharmacies, and other healthcare providers. In some cases it also earns income from product royalties and collaborations with other drugmakers. Because these are complex medicines used in specialized care, Biogen’s business depends on scientific research, regulatory approval, and ongoing relationships with neurologists, specialists, and payers who decide whether patients can access the treatments.

What makes Biogen different is that it sits at the high-science end of the pharmaceutical chain: it turns research in biology and neurology into treatments for hard-to-treat diseases. Instead of competing on broad, everyday medicines, it focuses on a smaller set of branded therapies where patient need is high and medical expertise matters. That gives Biogen a business model built around patents, clinical data, specialist prescribing, and close ties to the healthcare system.